news

on september 13, a beijing business daily reporter learned at the 2024 china international fair for trade in services that china-us family healthcare group successfully held a launch meeting for its international medical platform and announced that its tertiary sino-foreign joint venture hospital will be officially put into use by the end of this year.

hu lan, founder and ceo of amcare, said that amcare became a member of douyin's medical service sector in 2022. this strategic cooperation has injected new vitality and resources into amcare and accelerated the pace of innovation and upgrading of medical services. with this advantage, amcare's international medical platform has achieved many achievements and progress, including the construction of a multidisciplinary platform and an international diagnosis and treatment model, the successful operation of a clinical translational scientific and technological innovation platform, the continuous expansion of international diagnosis and treatment services, the continuous deepening of global exchanges and cooperation, and the optimization of diagnosis and treatment services for foreign affairs and foreign personnel.

"after the new tertiary sino-foreign joint venture hospital is put into use, amhealth will be more actively involved in the research and application of medical technology, and provide patients with more accurate and efficient medical services through a multidisciplinary international cooperation diagnosis and treatment model," said hu lan.

beijing business daily reporter learned that amcare is currently actively promoting the research and application of medical technology, with medical ai and gene cell therapy as the key directions of efforts. in terms of medical ai, it involves ai pre-diagnosis, ai fetal heart monitoring, ai gastroscopy, etc.; in terms of gene cell therapy, it involves new car-t cell therapy technology and tils cell therapy technology.

ai pre-diagnosis can simulate doctors collecting pre-diagnosis information from patients in advance, identify dozens of consultation intentions, and accurately judge patients' complaints. based on the medical knowledge map, it can ask patients about their conditions in a personalized way and automatically generate standardized cases based on the standard requirements for medical record writing.

ai fetal heart rate monitoring is different from traditional fetal heart rate monitoring. it has real-time interpretation capabilities. it can identify abnormalities in real time based on interpretation rules. abnormal results are displayed in a pop-up window on the doctor's mobile phone in the form of message push. doctors are not restricted by region, and can understand the situation at the first time and guide clinical operations immediately. the unique file marking and management function can mark, modify and review historical data at any time to achieve systematic management of fetal heart rate monitoring data.

the ai ​​gastroenteroscopy has the functions of intestinal cavity positioning and time statistics during the stage of inserting the endoscope; during the stage of withdrawing the endoscope, it has the functions of withdrawing the endoscope speed and time statistics to avoid missed diagnosis due to too fast operation speed. during the withdrawal process, the cleanliness of the intestinal cavity can be tested according to the boston-level score, and the intestinal preparation can be evaluated in real time. at the same time, the lesion detection and classification function of the ai ​​gastroenteroscopy can automatically detect the lesion area and type, help doctors make differential diagnoses, assist clinical judgments, and reduce misdiagnosis and missed diagnoses.

cell therapy is a technology that extracts immune cells from the patient's body, transforms and expands them into living cell drugs in vitro, and then returns them to the patient to treat cancer. the us-china research center has cooperated with peking university cancer hospital to develop a new generation of cart technology that can eliminate the inhibitory effect of the tumor immune microenvironment on cart cells and promote the long-term survival of cart cells in the body. the project is currently conducting clinical research with peking university cancer hospital as the center.

tils tumor infiltrating lymphocyte therapy extracts t cells from the patient's tumor tissue, and then amplifies these cells in vitro before returning them to the patient. the us-china research center has begun to cooperate with multiple oncology departments at airui to conduct preliminary explorations based on tumor tissues of multiple cancer types, including gastrointestinal tumors, ovarian tumors, lung cancer, and breast cancer, to explore the scope of application of tils technology and its possibilities in the treatment of different cancer types.

beijing business daily reporter wang yinhao